31 East 62nd Street
New York, NY 10065
United States
212 672 9100
https://www.siga.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 45
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Daniel J. Luckshire | Executive VP, CFO & Secretary | 1.42M | N/D | 1971 |
Dr. Dennis E. Hruby Ph.D. | Executive VP & Chief Scientific Officer | 1.41M | N/D | 1952 |
Dr. Jay K. Varma M.D. | Executive VP, Chief Medical Officer & Director | 1.04M | N/D | 1972 |
Dr. Diem Nguyen M.B.A., Ph.D. | CEO & Director | N/D | N/D | 1972 |
Ms. Tove C. Bolken | Senior VP of Operations & Chief Supply Chain Officer | N/D | N/D | N/D |
Mr. Herb Vloedman | Senior VP & Chief Information Officer | N/D | N/D | N/D |
Mr. Lawrence R. Miller Esq., J.D. | General Counsel | N/D | N/D | 1968 |
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
La calificación ISS Governance QuickScore de SIGA Technologies, Inc. a partir del 29 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 9; Derechos del accionista: 2; Compensación: 8.